Published by MyelinWatch:
Rutgers mGluR5 agonists · Researchers are developing small molecules that activate mGluR5, a receptor involved in signalling that may influence myelin-making cells.
Researchers are developing small molecules that activate mGluR5, a receptor involved in signalling that may influence myelin-making cells.
Not tested in people
Research so far is in laboratory cells or animal models.
Activity has been reported in human myelin-making cells and animal models. The work remains at the laboratory-and-animal research stage; no benefit in people with MS is known.
These molecules are not treatments. A development partner and further work are still needed before human testing.
Rutgers presented new small molecules that act on a receptor called mGluR5. They increased production of myelin proteins in human cells in the laboratory and showed activity in animal models.
Source: Rutgers Innovation Ventures — university technology-transfer page ↗
